At 7.2% CAGR, the North America Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market is Projected to be Worth US$ 885.4 Million by 2030, says Business Market Insights

According to Business Market Insights research, the North America fluorescence in-situ hybridization (FISH) imaging systems market was valued at US$ 507.0 million in 2022 and is expected to reach US$ 885.4 million by 2030, registering a CAGR of 7.2% from 2022 to 2030. Rising prevalence of target disorders and increasing R&D investments in in-vitro diagnostics attributed to the North America fluorescence in-situ hybridization (FISH) imaging systems market expansion.        

FISH is a powerful molecular cytogenetic technique that allows the visualization and localization of specific DNA sequences within cells or tissues. This technology has revolutionized the field of genetics and diagnostics, providing researchers and clinicians with valuable insights into genetic abnormalities, chromosomal rearrangements, and various diseases. The increasing prevalence of target disorders such as genetic syndromes and cancer, and other genetic anomalies drives the demand for FISH imaging systems. According to the National Library of Medicine, the US is expected to record 1.96 new cancer cases and 609,820 cancer deaths in 2023. The demand for accurate and reliable diagnostic tools surges with the continued rise in the prevalence of these target disorders. FISH imaging systems provide high-resolution images to aid the detection of subtle genetic changes, enabling early disease diagnosis and personalized treatment approaches. These disorders often involve genetic mutations or variations that can be accurately identified and characterized using FISH imaging systems. The ability to precisely map the location of specific genes or DNA sequences within cells has proven crucial for understanding disease mechanisms, developing targeted therapies, and making informed clinical decisions. A prominent advantage of FISH lies in its ability to work with various sample types, including formalin-fixed paraffin-embedded tissues, cytological preparations, and fresh tissues. This versatility has made FISH an essential tool in both research and clinical settings, allowing the identification of genetic markers associated with diseases such as leukemia, lymphoma, solid tumors, and congenital disorders.

On the contrary, high cost of fish imaging systems and procedures hampers the North America fluorescence in-situ hybridization (FISH) imaging systems market.  

Based on product, the North America fluorescence in-situ hybridization (FISH) imaging systems market is segmented into instruments, consumables, accessories, and software. The consumables held 54.3% share of North America fluorescence in-situ hybridization (FISH) imaging systems market in 2022, amassing US$ 249.6 million. It is projected to garner US$ 442.3 million by 2030 to expand at 7.4% CAGR during 2022–2030. 

In terms of application, the North America fluorescence in-situ hybridization (FISH) imaging systems market is segmented into cancer diagnosis, genetic disease diagnosis, infectious disease diagnostic, and others. The cancer diagnosis segment held 48.6% share of North America fluorescence in-situ hybridization (FISH) imaging systems market in 2022, amassing US$ 246.4 million. It is projected to garner US$ 441.0 million by 2030 to expand at 7.5% CAGR during 2022–2030.

Based on end users, the North America fluorescence in-situ hybridization (FISH) imaging systems market is segmented into diagnostic laboratories, contract research organizations, pharmaceutical and biotechnological companies, and others. The diagnostic laboratories segment held 78.2% share of North America fluorescence in-situ hybridization (FISH) imaging systems market in 2022, amassing US$ 396.5 million. It is projected to garner US$ 695.9 million by 2030 to expand at 7.3% CAGR during 2022–2030.

By country, the North America fluorescence in-situ hybridization (FISH) imaging systems market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 82.8% share of North America fluorescence in-situ hybridization (FISH) imaging systems market in 2022. It was assessed at US$ 419.74 million in 2022 and is likely to hit US$ 733.71 million by 2030, exhibiting a CAGR of 7.2% during 2022–2030.      

Key players operating the North America fluorescence In-Situ Hybridization (FISH) Imaging Systems Market Euroclone SpA, TissueGnostics GmbH, Agilent Technologies Inc, Abnova Taiwan Corp, BioGenex Laboratories Inc, Leica Biosystems Nussloch GmbH, MetaSystems Probes GmbH, Bio-View Ltd, Thermo Fisher Scientific Inc, and Applied Spectral Imaging, among others.

• Bio-View Ltd in Apr-2023, Partnership ANGLE Plc, a global leader in liquid biopsy, entered into a collaboration with BioView Ltd to develop a liquid biopsy circulating tumor cell (CTC) HER2 assay for breast cancer using ANGLE's FDA-cleared Parsortix PC1 Clinical System to harvest CTCs and BioView's automated microscopy systems and software to detect and assess HER2 expression and/or gene amplification in CTCs.
• Thermo Fisher Scientific Inc in Jan-2023, Mergers and Acquisitions Thermo Fisher Scientific Inc, the world leader in serving science, had completed its acquisition of The Binding Site Group, a global leader in specialty diagnostics, from a shareholder group led by Nordic Capital in an all-cash transaction valued at GBP 2.3 billion, or US$ 2.8 billion at current exchange rates. The Binding Site adds pioneering innovation in diagnosis and monitoring for multiple myeloma to the existing specialty diagnostics portfolio. Early detection and informed treatment decisions can substantially impact patient outcomes.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com